Jounce Therapeutics Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Jounce Therapeutics stock.
View analyst ratings for Jounce Therapeutics or view top-rated stocks.

Wall Street analysts have given Jounce Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Jounce Therapeutics.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) issued its earnings results on Thursday, August, 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.28. The company had revenue of $25.37 million for the quarter, compared to the consensus estimate of $9.48 million.
View Jounce Therapeutics' earnings history.

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JNCE stock has increased by 82.0% and is now trading at $7.79.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued 12 month target prices for Jounce Therapeutics' shares. Their forecasts range from $10.00 to $17.00. On average, they expect Jounce Therapeutics' share price to reach $14.25 in the next year. This suggests a possible upside of 82.9% from the stock's current price.
View analysts' price targets for Jounce Therapeutics or view top-rated stocks among Wall Street analysts.

45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among Jounce Therapeutics' employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Jounce Therapeutics include Century Therapeutics (IPSC), Ocugen (OCGN), AlloVir (ALVR), Replimune Group (REPL), Immunocore (IMCR), Monte Rosa Therapeutics (GLUE), Inhibrx (INBX), Scholar Rock (SRRK), Sangamo Therapeutics (SGMO), Vaxcyte (PCVX), Valneva (VALN), Agenus (AGEN), Atara Biotherapeutics (ATRA), Icosavax (ICVX) and Krystal Biotech (KRYS).
View all of JNCE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include TRV GP II LLC (8.68%), BlackRock Inc. (4.80%), Vanguard Group Inc. (2.75%), Dimensional Fund Advisors LP (2.40%), FMR LLC (1.54%) and Credit Suisse AG (1.07%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray and Rock Ventures Ii LP Third.
View institutional ownership trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including TRV GP II LLC, Victory Capital Management Inc., Wells Fargo & Company MN, Citadel Advisors LLC, Schonfeld Strategic Advisors LLC, AXA S.A., Bank of America Corp DE, and State of Wisconsin Investment Board. Company insiders that have sold Jounce Therapeutics company stock in the last year include Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, and Rock Ventures Ii LP Third.
View insider buying and selling activity for Jounce Therapeutics or view top insider-selling stocks.

JNCE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Congress Asset Management Co. MA, Geode Capital Management LLC, Northern Trust Corp, Dimensional Fund Advisors LP, JPMorgan Chase & Co., and Marshall Wace LLP.
View insider buying and selling activity for Jounce Therapeutics or or view top insider-buying stocks.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JNCE stock can currently be purchased for approximately $7.79.

Jounce Therapeutics has a market capitalization of $399.08 million and generates $62.34 million in revenue each year. The company earns $-43,840,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

Jounce Therapeutics employs 128 workers across the globe.

The official website for Jounce Therapeutics is www.jouncetx.com.

Jounce Therapeutics is headquartered at 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3840 or via email at [email protected].